The $3 Morning
Six hundred million dollars. That is what AG1 projects it will collect in fiscal year 2024 — roughly $50 million a month, or $1.6 million a day — from a single product, sold through a single channel, at a price point of roughly $2.63 per serving for subscribers. The product is a moss-green powder that dissolves in cold water. It tastes faintly of vanilla and pineapple. A twelve-gram scoop contains 75 vitamins, minerals, probiotics, adaptogens, and whole-food-sourced ingredients. That's the pitch. The reality is both simpler and stranger: AG1 is perhaps the most successful consumer product ever built almost entirely on the back of podcast advertising, a business that reached $150 million in revenue by 2021 and then quadrupled to a projected $600 million in three years — while remaining direct-to-consumer, subscription-first, and profitable. The company reached a $1.2 billion valuation in January 2022. It has never been publicly traded. And until very recently, it sold exactly one thing.
The strangeness deepens. AG1 operates in the dietary supplement industry, a $60-billion-plus U.S. market that the FDA regulates with a famously light touch — products need not prove efficacy before going to market, and claims of "supporting" bodily functions sit in a regulatory gray zone that allows extraordinary latitude. AG1's scientific research has been questioned by nutritionists, journalists, and at least one Harvard Medical School professor. Its founder was convicted on 47 criminal and civil counts in New Zealand in 2011 for a rent-to-own real estate scheme targeting low-income tenants — a fact that remained largely unreported in American media until 2024. He stepped down as CEO months later. And yet. The product moves. Subscriptions renew. The forest-green pouch appears in Gwyneth Paltrow's refrigerator, in Lewis Hamilton's morning routine, in the opening sixty seconds of seemingly every health-adjacent podcast on earth. The question is not whether AG1 is a good supplement — scientists disagree on that, and this is not a nutrition review. The question is how a single SKU, born in obscurity, manufactured originally on the other side of the planet, built a half-billion-dollar subscription machine by weaponizing trust at scale.
By the Numbers
The AG1 Machine
~$600MProjected annual revenue (FY2024)
$1.2BValuation (Jan 2022 funding round)
$115MTotal venture capital raised
1Core product (AG1 powder)
75Ingredients per 12g serving
~$2.2M/moEstimated podcast ad spend
$79/moSubscription price ($99 one-time)
16Countries with AG1 employees
A Kiwi in Phoenix
Chris Ashenden's origin story, as he told it for over a decade, had the clean arc of a wellness parable. A New Zealander who studied sports science at the University of Auckland, a former rugby player, a man who despite thinking he knew everything about nutrition found himself chronically sick. By 2008 — in Ashenden's telling — he'd landed at a clinic in Phoenix, Arizona, where he spent $35,000 on blood, stool, and saliva tests only to learn he wasn't absorbing nutrients properly. The clinic's solution: a customized regimen of roughly 50 pills a day at $100 per day. "Most of what we think we know about nutrition is wrong," Ashenden later recounted, "and there's gotta be a better way." He spent the next year working with naturopaths and formulators to compress the supplement stack into a single powder. AG1's customer number one was Ashenden himself. His parents were numbers two and three.
The story left things out. In 2010 and 2011, New Zealand's Commerce Commission prosecuted Ashenden and two business partners for a rent-to-own housing scheme that a judge found had "strong elements of cynicism" and constituted "calculated exploitation of people struggling financially." The court entered convictions — 47 counts spanning criminal and civil charges. Ashenden was fined and ordered to pay restitution totaling nearly $200,000 NZD. He declared bankruptcy. He left New Zealand. When journalist Scott Carney exposed this history in May 2024, AG1 hired Megan Meier — the attorney behind the $787 million Fox News defamation judgment — to challenge the reporting. The legal strategy backfired: Carney's investigation went viral, and Ashenden stepped down as CEO within months. Carney later claimed the company lost $45 million in subscription revenue as fallout.
None of this erases the commercial achievement. Ashenden may have been a flawed messenger, but the message — that modern diets leave nutritional gaps, and a single daily habit could address them — was precisely calibrated for a moment that hadn't quite arrived when he founded the company in 2010. It would take the rise of podcasting, the pandemic-era wellness explosion, and a decade of patient product iteration before the moment and the message converged.
The Decade in the Wilderness
AG1's early years were neither glamorous nor fast. The product launched in 2010 from New Zealand, manufactured in a TGA-registered facility. Ashenden initially sold on Amazon before migrating to a direct-to-consumer model — a decision that looked foolish at the time and brilliant in retrospect. Without retail distribution, without significant capital (the company was bootstrapped until 2021), growth depended on word-of-mouth and the emerging ecosystem of health-focused content creators.
From founding to unicorn status
2010Chris Ashenden launches Athletic Greens from New Zealand; begins DTC sales.
~2012Early podcast sponsorships begin, including with Tim Ferriss; Andrew Huberman later claims he's been using AG1 since 2012.
2018Formula undergoes significant iteration; company begins scaling podcast ad strategy across health and fitness shows.
2021Revenue reaches ~$150M. Kat Cole joins as President, COO, and board member in December. Company rebrands from Athletic Greens to AG1.
2022Raises $115M led by Alpha Wave Global; valuation reaches $1.2B. Mark Vadon (Zulily, Blue Nile, Chewy) joins board.
2024Projected revenue of $600M. Ashenden steps down as CEO; Kat Cole assumes CEO role in July. Company begins planning retail expansion.
2025
The first inflection point came through Tim Ferriss. Ashenden, who had cultivated a personal blog under the handle "Chris the Kiwi," moved through the overlapping circles of biohacking, Paleo nutrition, and self-optimization that Ferriss helped popularize with
The 4-Hour Body. Ferriss endorsed Athletic Greens on his podcast — at the time one of the most popular shows in the world — and the affiliate model was born. Listeners heard a host they trusted describe a product they used. They clicked a custom landing page. They subscribed. The CAC on a podcast read, in those early days, was extraordinarily low compared to Facebook or Google advertising, because the trust transfer was so direct, the audience so targeted, and the competition for podcast ad inventory almost nonexistent.
By the mid-2010s, Athletic Greens was spending meaningfully on podcast sponsorships and building a playbook that other DTC brands would later attempt to copy. The formula was straightforward: identify podcasters with loyal, health-conscious audiences; offer generous affiliate commissions and free product; provide customized landing pages that tracked conversions by show; then reinvest the revenue into more sponsorships. The machine fed itself. Each new endorsement — Joe Rogan, Andrew Huberman, Peter Attia, Kara Swisher and Scott Galloway on
Pivot, Jason and Travis Kelce on
New Heights — widened the funnel while maintaining the crucial ingredient: parasocial trust.
We have a business that solves a problem, and we are very good at solving that problem. This is a problem that is valid; it is relevant for literally tens of millions of people around the world.
The [Trust](/mental-models/trust) Machine
What AG1 built was not, strictly speaking, an advertising strategy. It was a trust arbitrage engine. The insight — obvious now, radical when Ashenden first committed to it — was that in a supplement industry rife with dubious claims and opaque manufacturing, the bottleneck to growth was not awareness but credibility. And credibility, in the 2010s, was migrating from institutions (the FDA, doctors, consumer reports) to individuals (podcasters, YouTubers, Instagram wellness accounts). AG1 didn't just buy ad reads. It bought the accumulated reputational equity of every host who said "I take this every morning."
The mechanics were precise. AG1 reportedly spent approximately $2.2 million per month on podcast advertising — a staggering sum for a single-product company, but one that yielded extraordinary returns because of the subscription model's economics. A subscriber paying $79 per month who retained for even twelve months generated nearly $950 in revenue. The company claimed profitability, suggesting that the lifetime value of acquired subscribers comfortably exceeded even expensive acquisition costs. And the podcast channel, unlike Facebook or Google, had a structural advantage: ad reads were integrated into content, voiced by the host, and often personalized with anecdotes about the host's own morning routine. They could not be skipped the way a pre-roll YouTube ad could. They were, in effect, endorsements disguised as advertisements — or advertisements elevated to endorsements, depending on your level of cynicism.
AG1 is a science-backed solution for energy, focus, and high performance.
The risk, of course, was concentration. AG1's brand was downstream of every host's reputation. When Andrew Huberman faced allegations in early 2024 about his personal conduct, AG1's association with "Huberman husbands" — the masculine-coded health optimization demographic that followed the neuroscientist's every recommendation — became a liability as much as an asset. When podcasters themselves came under scrutiny for undisclosed affiliate economics, the entire trust-transfer model wobbled. AG1 had built its castle on borrowed credibility. The rent was cheap until it wasn't.
The Religion of One Product
Perhaps the most counterintuitive strategic decision AG1 made — and maintained for fourteen years — was refusing to launch a second product. In an industry where line extensions are the default growth lever, where every supplement brand rushes to stack SKUs the moment the first one gains traction, AG1 sold one powder. Period.
The discipline was theological in its intensity. Ashenden spoke about it with the fervor of a convert: the whole point of AG1 was to replace the supplement stack, not become one. Launching a protein powder or a sleep supplement would undermine the foundational narrative — that one scoop, one habit, one product could cover your bases. The constraint forced the company to iterate obsessively on the single formula, which has gone through more than 50 versions since launch, each tweaking ingredients, bioavailability, taste, and probiotic strains. The latest iteration, AG1 Next Gen, expanded the vitamin and mineral profile and adjusted sweetness without adding sugar.
The single-product discipline also created brutal operational simplicity. One supply chain. One manufacturing relationship. One set of quality certifications (AG1 is NSF Certified for Sport, tested for over 280 banned substances). One inventory management challenge. The company could pour every marginal dollar of R&D into making the one thing better rather than spreading resources across a portfolio. For a DTC subscription business, this was the equivalent of compounding interest — small improvements to retention, taste, and perceived efficacy accumulated year after year, reducing churn and increasing lifetime value in ways that a broader product line might actually have diluted.
The cost was also real. AG1 left enormous revenue on the table. The "foundational nutrition" positioning could have justified a Vitamin D supplement (AG1 notably doesn't contain Vitamin D or iron in sufficient standalone doses), a protein powder, a sleep aid, a hydration mix. Every one of these adjacencies represented a TAM measured in billions. Ashenden — and later Cole — said no. For fourteen years.
Until they didn't. In January 2025, Kat Cole announced at NRF that AG1 was "ready to start saying yes."
The Operator
Kat Cole is the kind of executive whose biography reads like a screenplay written by someone who studied American meritocracy as anthropology. Born in Jacksonville, Florida, in 1978, she grew up in a household fractured by her parents' divorce when she was nine. Her mother raised three daughters alone. Cole started working at Hooters as a hostess and waitress while attending the University of North Florida as an engineering major. At nineteen, Hooters asked her to travel internationally to help open franchise locations. She dropped out of college. By twenty, she held a corporate position — without a degree. Over fourteen years at the company, she climbed to vice president, eventually returning to school to earn an MBA from Georgia State University in 2010, becoming one of the rare executives to hold a master's degree without a bachelor's.
The Hooters years were formative in ways that transcended the obvious jokes. Cole learned to operate in an environment where external credibility was perpetually questioned, where mentors were scarce because of the brand's reputation, and where she had to develop internal frameworks for self-advocacy. One such framework — the "hotshot rule," in which she imagines someone she admires in her shoes and identifies the one thing they'd do differently, then acts on it within 24 hours — became a staple of her public speaking. "Every week I put in motion one thing I would not otherwise have," she told Fortune's Most Powerful Women Summit. "The compounding effect has been enormous."
From Hooters she moved to Focus Brands, the parent company of Cinnabon, Moe's Southwest Grill, Auntie Anne's, Jamba Juice, and others. At Cinnabon, she became president at 32 — the youngest CEO ever featured on Undercover Boss when her episode aired in 2012. She transformed Cinnabon from a mall-based bakery chain into a licensing empire: Cinnabon-branded products appeared in Taco Bell items, Burger King offerings, and some sixty grocery-store SKUs, pushing total Cinnabon-related product sales toward $1 billion. Fortune named her to its 40 Under 40 list in 2013. By 2015 she was group president of Focus Brands.
Then she left. In late 2020, after a decade at Focus Brands, Cole took what she called a "portfolio chapter" — angel investing (over 60 companies in wellness, web3, SMB tech, and omnichannel consumer products), advising startups, serving on boards. Athletic Greens was among the companies she advised. In December 2021, she joined as President, COO, and board member, writing on her Substack that she was drawn to "a brand I love, a business model I believe in, a mission that inspires me."
I miss doing the deepest work that can only be done from inside a company. Helping a business from the sidelines is great, but for me, while I'm so young and full of energy to create and lead, it's time to go back in.
When Ashenden stepped down in July 2024, Cole became CEO. She inherited a company that was printing cash from a single product but facing compounding headwinds: the founder's scandal, growing scientific skepticism, a podcast advertising ecosystem under scrutiny, and the existential question of whether AG1 could transition from a niche "Huberman husband" brand to a mass-market daily habit. Her first major move — announcing the expansion into retail and new products at NRF in January 2025 — was not the action of someone dismantling what came before. It was the action of someone who had spent three years studying the machine from the inside and concluded it was finally time to let it grow.
The Subscription Fortress
AG1's subscription model is the structural core of the business, and understanding its economics explains almost everything about the company's strategic choices. At $79 per month for subscribers ($99 for one-time purchases), AG1 is among the most expensive greens powders on the market — multiples more than competitors like Bloom Nutrition or Amazing Grass. The premium is the strategy.
The subscription creates three interlocking advantages. First, predictable recurring revenue — the company can forecast demand, manage inventory, and optimize its single supply chain with unusual precision. Second, high LTV relative to CAC — a subscriber who stays for twelve months generates roughly $948 in revenue, and given the company's reported profitability, the margin on that revenue is substantial enough to fund aggressive customer acquisition through expensive podcast sponsorships. Third, and most subtly, the subscription creates a behavioral commitment device. A customer who has signed up for auto-shipment, who has incorporated the morning scoop into their routine alongside coffee and teeth-brushing, who has the forest-green canister on their countertop, is far less likely to churn than someone making a repeat purchase decision each month. The product becomes invisible infrastructure — part of the morning, not a monthly choice.
AG1's welcome kit reinforced this with physical ritual design: a branded canister, a metal scoop, a shaker bottle, and free travel packs. These weren't accessories. They were behavioral anchors. The canister sits on the counter. The scoop is satisfyingly heavy. The shaker bottle goes to the gym. Every physical touchpoint reduces the cognitive friction of the daily habit and increases switching costs. To cancel AG1 isn't just to stop buying a powder — it's to remove an object from your counter, to break a morning sequence, to admit that the thing you told your friends about didn't work.
The churn dynamics are the black box. AG1 doesn't publicly disclose retention rates, but the revenue trajectory — from $150 million in 2021 to a projected $600 million in 2024, a quadrupling in three years — implies that either new subscriber acquisition is accelerating dramatically, retention is exceptionally strong, or both. Given the company's profitability claims, the math almost certainly requires solid retention: if subscribers were churning rapidly, the podcast acquisition costs would consume the margin.
The Science Question
AG1's relationship with science is — to put it carefully — complicated. The company claims its formula is "science-driven" and points to clinical trials and research partnerships. Its website features a research page that has expanded over time, including references to gold-standard randomized controlled trials. The product is NSF Certified for Sport, meaning it has been tested for over 280 banned substances and manufactured in GMP-compliant facilities — a meaningful quality credential that many competitors lack.
But the efficacy question is distinct from the quality question. When Fortune asked scientists about AG1's claims in early 2025, "the skepticism was intense." A Harvard Medical School professor and several nutritionists described the company's testing process as falling short of what would be necessary to substantiate its health claims. The central issue, as investigative journalist Scott Carney reported in May 2025, involves AG1's choice of placebo in its human studies. The company used maltodextrin as its control — a substance that AG1's own cited research from 2022 suggests can harm gut health. By comparing AG1 to a substance that may actively damage the outcome being measured, rather than using inert water as a baseline, the study design introduced what critics call a "home-team advantage." Even with this design, Carney reported, the only published human study showed "no substantial difference between maltodextrin and AG1."
AG1 has pushed back against these characterizations, expanding its research section and pointing to upcoming publications. The company's position — that maltodextrin is a common placebo in microbiome research, that its formula is continuously improved based on the latest science, and that NSF Certification provides meaningful quality assurance — is not unreasonable. But it is also not the same as demonstrating that a twelve-gram scoop of powder meaningfully improves health outcomes beyond what a balanced diet and a basic multivitamin would provide.
This tension — between rigorous quality control and unproven efficacy claims — is not unique to AG1. It is the structural condition of the entire U.S. dietary supplement industry, which operates in a regulatory space where products can make "structure/function" claims (supports immune health, promotes digestive function) without FDA pre-market approval. AG1 is not breaking rules. It is playing the game as the rules allow it to be played, with more polish and better marketing than most. Whether that is admirable or alarming depends entirely on your priors.
The Backlash and the Moat
The year 2024 was AG1's trial by fire — and, paradoxically, a demonstration of the brand's resilience. In May, Scott Carney published his investigation into Ashenden's criminal past in New Zealand. AG1's aggressive legal response — deploying the attorney who had won $787 million from Fox News — backfired spectacularly, generating a Streisand effect that amplified the story far beyond what a Substack post would normally reach. Ashenden stepped down as CEO within months. The Today Show, the New York Times, and Bryan Johnson (the tech millionaire pursuing a controversial anti-aging regimen) all questioned AG1's claims. YouTube debunkers produced forensic ingredient analyses. Dietitians pointed out that AG1 uses proprietary blends, making it impossible for consumers to know the exact dose of any individual ingredient.
And yet the revenue kept growing. From $150 million in 2021 to a projected $600 million in 2024. The company's claim that Carney's reporting cost it $45 million in subscription revenue — even if true — represents less than 8% of projected annual revenue, suggesting that the vast majority of subscribers either didn't see the reporting, didn't care, or had already integrated AG1 so deeply into their routines that switching costs exceeded the discomfort of the scandal.
This is the paradox at the center of AG1's business: the trust that built it is not institutional trust (in science, in regulation, in the founder's character) but habitual trust — the trust that comes from doing something every morning for months or years, from feeling okay, from the product being part of who you are. Habitual trust is both fragile (it can shatter if someone gets sick) and extraordinarily durable (it resists rational argument). People don't cancel their morning coffee because a study questions caffeine's long-term effects. They don't cancel AG1 because a journalist questions maltodextrin placebos.
The Expansion Gamble
In January 2025, Kat Cole stood on a stage at NRF alongside Shopify president Harley Finkelstein and outlined AG1's next chapter. After fifteen years of saying no — no to retail, no to new products, no to Amazon — the company was ready to say yes.
The expansion had three prongs. First, retail distribution: AG1 launched nationwide at over 600 Costco stores in mid-2025, its first major brick-and-mortar presence, while also placing product in airport vending machines, 1 Hotels, True Food Kitchen, and Starbucks partnerships. Second, product expansion: the first new SKU beyond the original powder, with AG1 Tropical (a new flavor variant) and AG1 Vitamin D3+K2 oil, plus an expansion called AGZ for different usage occasions. Third, geographic expansion: Tim Harrington, CEO for Asia-Pacific based in Singapore, was leading launches into Taiwan, Hong Kong, and broader APAC markets.
Cole articulated three preconditions the company required before expanding: strengthened supply chain (moving some production from New Zealand to the U.S.), completed clinical trials to support a "science-driven message" that would hold up on retail shelves, and a team with retail experience — including Paulie Dery, the former CMO of Yeti, hired in August 2024. The logic was sound. But the risk was real.
It's like, white knuckle all the way where we're like, 'Oh my gosh, what's the site experience gonna be? Everybody's used to seeing only one thing — what happens when they have the option for two?'
The DTC-to-retail transition has destroyed more brands than it has scaled. The dynamics are treacherous: retail partners demand lower wholesale prices, compressing margins; the brand loses control of the customer relationship and the data that comes with it; shelf presence requires trade spend, slotting fees, and promotional velocity that DTC companies have no muscle memory for; and the premium positioning that works online — where the customer experience is curated, the landing page tells the story, the podcast host provides the endorsement — collapses on a shelf next to competitors selling similar-looking green powder for a third of the price.
Finkelstein, speaking alongside Cole, offered a framework that suggested a more nuanced approach: the point of retail, he argued, was not necessarily acquiring new customers but increasing the LTV of existing ones and reducing CAC. A Costco customer who discovers AG1 in-store and later subscribes online may be cheaper to acquire than a podcast listener, particularly as digital advertising costs have skyrocketed. The physical store becomes a top-of-funnel acquisition channel — less a revenue center than a marketing expense with a physical footprint.
Whether this framing holds will determine AG1's next act. The company has spent fifteen years perfecting a one-product, one-channel business. The transition to multi-product, multi-channel — while maintaining the subscription fortress, the premium positioning, and the behavioral habit loop — is arguably harder than building the original machine.
The Green Counter
In the pantry of modern American aspiration, AG1's forest-green pouch occupies a specific and revealing position. It sits alongside the Peloton, the Oura Ring, the Stanley cup, and the Theragun — objects that signal not wealth exactly, but investment in self, the performative discipline of someone who has decided that their body is an optimization project. The pouch costs less than a gym membership but more than a multivitamin. It is visible on kitchen counters in Instagram posts and podcast studio backgrounds. It photographs well. The branding — lowercase, clean, muted greens and whites — communicates the opposite of the screaming neon that characterizes most supplement packaging. It whispers. The whisper says: I take this seriously. I am not the kind of person who buys supplements at GNC.
This aesthetic positioning is not accidental. AG1's branding overhaul — from "Athletic Greens," which coded as jock-adjacent, to "AG1," which codes as sleek and vaguely clinical — was a deliberate move to expand the addressable market beyond athletes and biohackers to the broader "wellness-curious" consumer. The rebrand coincided with the product's crossover from the Joe Rogan demographic to the Kara Swisher demographic, from CrossFit gyms to Goop readers, from Andrew Huberman's audience to Gwyneth Paltrow's refrigerator.
The company's impact report reveals a business with global ambitions carefully wrapped in purpose language: 15.7 million meals provided to food-insecure children since 2019 through partnerships with No Kid Hungry and World Central Kitchen; 196 suppliers onboarded in a traceability platform; a 29% year-over-year team growth rate across 16 countries; a remote-first organizational structure. These are the table stakes of any consumer brand aspiring to premium positioning in the 2020s — but AG1 executes them with more specificity than most, investing in Sourcemap for supply chain tracing and Watershed for carbon footprint measurement.
The deeper question is whether AG1 is a supplement company or a habit company. The product may or may not meaningfully improve your nutritional status. But the morning ritual — scoop, shake, drink, feel virtuous — demonstrably improves something: the consumer's sense of agency over their own health. In an era of pandemic anxiety, chronic disease, and institutional distrust, that sense of agency has a market price. AG1 discovered it was $79 a month.
The Machine at Dawn
There is a specific detail from AG1's 2024 impact report that captures something essential about the company. Under the "One Spectacular Life" section — AG1's internal culture framework — the report notes that 50 employees participated in one-on-one coaching sessions, with 84% describing their coaching as "life changing" or "amazing." The 2024 internal engagement survey, called "The Scoop," achieved a 96% participation rate with a grand mean engagement score of 4.07 out of 5.
These are small numbers. Fifty coaching participants in a company growing 29% year-over-year. An engagement survey with a name that puns on the product. But they reveal the operating philosophy that Kat Cole brought from her decades at Hooters, Cinnabon, and Focus Brands: the belief that internal culture is the precondition for external brand authenticity, that you cannot sell a "daily ownership of health" narrative to consumers while your own employees are burning out, that the habit loop works at every scale — individual morning routines, team engagement rituals, organizational commitment devices.
As AG1 enters 2025, the machine stands at an inflection point more consequential than any it has faced. The single-product purity that defined the brand for fifteen years is giving way to managed complexity. The DTC fortress is opening gates to Costco, airports, and hotel lobbies. The founder whose personal story anchored the brand mythology has been replaced by an operator whose story — Hooters waitress to unicorn CEO — is arguably more compelling and certainly less legally complicated. The podcast advertising moat that drove $600 million in revenue is under competitive pressure as every DTC supplement brand has now copied the playbook. And the scientific scrutiny that the company deflected for years is intensifying as the brand scales beyond the true-believer audience into the mainstream.
The counter in a house in Santa Monica. Dawn light. A woman reaches for the forest-green canister, scoops twelve grams of powder into cold water, shakes. She does not think about maltodextrin placebos, New Zealand court records, or podcast affiliate economics. She thinks: This is what I do in the morning. She drinks. The subscription renews.
